GlaxoSmithKline provides U.S. government with anthrax therapy

Sept. 20, 2013 at 1:40 AM   |   Comments

WASHINGTON, Sept. 20 (UPI) -- GlaxoSmithKline and the Biomedical Advanced Research and Development Authority, part of the U.S. government, signed a contract for anthrax treatment.

Sheri Mullen, vice president of Immunology & Rare Diseases, U.S. Pharmaceuticals, GSK, said the four-year agreement calls for the provision of its inhalation anthrax treatment, raxibacumab. The U.S. government is purchasing the medicine as a counter measure against a potential bioterrorist attack.

Under the terms of the contract, GSK will provide 60,000 doses of raxibacumab to the U.S. government over four years, at a value of approximately $196 million, Mullen said.

Raxibacumab was approved by the U.S. Food and Drug Administration in December 2012 for the treatment of adult and pediatric patients with inhalation anthrax due to Bacillus anthracis in combination with appropriate anti-bacterial drugs, and for inhalation anthrax when alternative therapies are not available or are not appropriate, Mullen said.

Anthrax is a rare and lethal disease, caused by a toxin-producing bacterium. Antibiotics target the anthrax bacteria, while raxibacumab offers an additional mechanism of action by blocking the activity of the anthrax toxin, which plays a key role in the progression of the disease, Mullen said.

© 2013 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Recommended UPI Stories
Most Popular
Fewer prescription pill overdoses in medical marijuana states
New data shows Melbourne is most well-rested city in the world
New research details rare cancer that killed Bob Marley
Poll: 26 percent of Americans believe they will get Ebola
Daughters more likely than sons to care for elder parents
Trending News